TABLE 4.
Selected novel putative ORFs
| ORFa | No.b | Result ofc:
|
Genome positiond (nucleotides) | Orientatione | ORF length (amino acids) | Selected clone region (nucleotides) | Opposite ORFf | Name of opposite ORF productf | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Peptide ELISA | RT-PCR | NB | ||||||||
| PSAN1 | 6 | ND | + | + | 1553-1443 | − | 37 | 1535-1464 | SAA0002 | Tetracycline resistance protein |
| SAN1 | 9 | N: 5/5 | + | ND | 11772-11671 | − | 34 | 11751-11708 | SA0008 | Histidine ammonia lyase |
| SAN2 | 8 | N: 4/5 | + | ND | 135574-135699 | + | 42 | 135601-135660 | SA0120 | Bacterial regulatory proteins, gntR |
| SAN3 | 9 | ND | + | ND | 301822-301718 | − | 35 | 301816-301743 | SA0263 | Peptidoglycan hydrolase |
| SAN4 | 69 | N: 4/5 | + | ND | 382929-382792 | − | 46 | 382878-382808 | SA0379 | phi PVL ORF 15 and 16 homologue |
| SAN5 | 7 | ND | − | ND | 1038052-1037975 | − | 26 | 1038085-1038018 | SA1028 | Hypothetical protein |
| SAN6 | 21 | ND | + | + | 1616061-1616270 | + | 70 | 1616109-1616161 | SA1579 | Conserved hypothetical protein |
| SAN7 | 86 | P: 36/42 N: 29/32 | + | + | 1858035-1858460 | + | 142 | 1858134-1858159 | SA1806 | LPXTG-motif cell wall protein |
| SAN8 | 5 | ND | + | ND | 2122207-2122449 | + | 81 | 2122291-2122377 | SA2055 | rsbW protein |
| SAN9 | 5 | ND | + | + | 2221258-2221758 | + | 167 | 2221486-2221680 | SA2150 | mrp protein |
| SAN10 | 256 | P: 34/42 | + | + | 2276258-2276142 | − | 39 | 2276261-2494441 | SA2194 | Hyaluronate lyase |
| N: 26/32 | ||||||||||
| SAN11 | 8 | N: 3/5 | − | ND | 2290161-2290319 | + | 53 | 2290173-2290241 | SA2208 | tRNA pseudouridine synthase A |
| SAN12 | 4 | ND | + | ND | 2723814-2723680 | − | 45 | 2723822-2723753 | SA2661 | Hypothetical protein |
| SAN13 | 3 | N: 3/5 | − | ND | 2728321-2728259 | − | 21 | 2728315-2728266 | SA2664 | Mannose-6-phosphate isomerase |
a
Consecutive numbering of novel ORFs, SAN, S. aureus New; prefix P, localization on plasmid of S. aureus COL strain.
b
Number of selected clones located in the respective putative ORF.
c
Peptide ELISA results show reactivity with patient sera (P) or healthy-subject high-titer sera (N) (as described in reference 4). Expression analysis by RT-PCR and Northern blotting (NB) were also carried out. ND, not determined.
d
Position of the putative ORFs on the genome according to CMR database (20).
e
Orientation of the putative ORFs on the plus strand (+) or negative strand (−) of the genome.
f
The opposite ORF and its name are the ORF number and name of the gene that is located in antisense direction to the putative novel ORF.